Drug Pricing And User Fees: CBER Will Need To Build Up As Gene Therapies Become More Popular

 
• By Ramsey Baghdadi

A quickened shift toward gene therapies for small populations may be the result of the new Medicare drug pricing law given protections afforded to those types of products.

green double helix
The recently-passed IRA might evently impact allocations in PDUFA VIII because of how Medicare pricing changes could alter which products are developed. • Source: Shutterstock

More from United States

More from North America